Hi Led. Very true.

I'm not a trader so I seldom look at volumes and share price however, given the low recent volumes and languishing share price I just checked today's volume and it is roughly 51,000 shares vs the 65 day average of approx 22,000 and the share price is up to $1.41. Seems to me that volume has been around 5,000 share a day lately. I should check.

This looks like someone(s) is/are taking notice. From what I have observed conferences and investor presentations usually do not impact demand and sp.

I think we all know that this share price is ridiculously low for a phase 3 BETonMACE trial drug and we have discussed the drags on price such as lack of a NASDAQ listing and poor communications, etc. Analysts feel the sp should be in the $5 to $6 range. Eastern (Ken Dart) and NGN I'm sure feel that $6 is irrelevant. KD is not a billionnaire for no reason...I am sure he sees the true value in RVX and Zenith is beyound what I can imagine. Tundup hasn't posted lately but I suspect he/she could give a valuation based on a successful BETonMACE trial.

So I wonder what is up?

There are many excellent things happening with this company, most of all the science. And the science seems to reveal a multi-dimensional "engine" based on the selective BET (bromodomain and extra-terminal) inhibitor platform they started testing 8 to 10 years ago. This platform seems to be providing the basis for many Resverlogix compounds (particularly apabetalone which as we all know is in a phase 3 BETonMACE trial) and also all of the Zenith compounds with the FDA approved trial on metastatic prostate cancer. If I recall I believe Don said that RVX has something like 1500 compounds and Zenith has 2500...which I was shocked about and also suspicious about but now I must say I believe it. If even 1 or 2 more of these compounds becomes viable for another indication or 2 it again is a huge potential market(s).

From the abstract from the Alberta Epigentics session;

1. Apabetalone (RVX-208) is an orally active small molecule that was discovered in Alberta. It is the first BET inhibitor to enter into human trials for treating CVD. RVX-208 selectively inhibits the second binding domain of BET proteins from complexing with its natural ligand acetylated lysine marks on the tail of histones.
2. In so doing, RVX-208 modulates gene transcription and has effects on pathways known to play important roles in CVD risks including the complement, coagulation, inflammation, and metabolism as well as increasing levels of the apolipoprotein A-I (apoAI), the major protein in high density lipoprotein(HDL). In addition to preclinical studies in vitro and in vivo, RVX-208 has been tested in many human trials lasting up to 6 months that in total enrolled almost 1000 patients.
3. In post-hoc analysis of the most recent studies, patients with CVD receiving 200 mg/day of RVX-208 had a 55% relative risk reduction in major adverse cardiac events (MACE) compared to placebo.

So generally we know that share price does not move based on why I am in the stock - which is the science.

The sp movement is small but I would guess that if it is related to the next regional deal it could accelerate, but of course I have no idea. Those in the "know" will fuel the market IMHO.

As I have posted before the failure of CEPT inhibitors and the fact that the medical and scientific community "thought that approach (CEPT inhibition) would be a breakthrough" may now turn their attention to BET inhibitors and this goes way beyond cardiovascular issues to so many diseases.

I have been very critical of Don but I believe he is a shrewd chess player. He knows that he has 7 million shares in a gold mine (actually 14 million shares in 2 gold mines) and he is smiling and as he said about the Zenith Capital royalties it will provide a huge reward for all of the RVX/Zeniith employees that have worked so hard for 15 years.

Just my rant.

GLTA

Cheers

Toinv